AnaptysBio, Inc. (NASDAQ:ANAB) produced a 436.98% rally since recording the worst price of $15.17. Thanks to the latest 4.2% increase, it now trades at $81.46. Throughout the trading on 11/24/2017, the share price floated between $78.475 and $83.5. This company shares are 7.57% off its target price of $87.63 and the current market capitalization stands at $1.85B. The recent change has given its price a 44.78% lead over SMA 50 and -0.48% deficit over its 52-week high. The stock witnessed 22.37% gains, 241.55% gains and 216.96% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ANAB’s volatility during a week at 5.64% and during a month it has been found around 5.26%.AnaptysBio, Inc. (ANAB) Top Holders
Institutional investors currently hold around $1.39 billion or 82% in ANAB stock. Look at its top three institutional owners. Frazier Management Llc owns $288.36 million in AnaptysBio, Inc., which represents roughly 15.59% of the company’s market cap and approximately 20.78% of the institutional ownership. Similar statistics are true for the second largest owner, Fmr Llc, which owns 2,192,030 shares of the stock are valued at $171.37 million. The third largest holder is Bvf Inc/Il, which currently holds $107.82 million worth of this stock and that ownership represents nearly 5.83% of its market capitalization.AnaptysBio, Inc. 13F Filings
At the end of 09/30/2017 reporting period, 56 institutional holders increased their position in AnaptysBio, Inc. (NASDAQ:ANAB) by some 6,677,740 shares, 16 decreased positions by 3,004,522 and 5 held positions by 8,074,071. That puts total institutional holdings at 17,756,333 shares, according to SEC filings. The stock grabbed 25 new institutional investments totaling 3,880,275 shares while 5 institutional investors sold out their entire positions totaling 229,323 shares.AnaptysBio, Inc. (NASDAQ:ANAB) Insider Trades
Multiple company employees have indulged in significant insider trading. AnaptysBio, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that 10% Owner Novo Holdings A/S has sold 356,300 shares of AnaptysBio, Inc. (ANAB) in trading session dated Aug. 21, 2017. These shares are worth $7,517,930 and were traded at $21.1 each. The SEC filing shows that Novo Holdings A/S performed a sale of 178,600 shares. The 10% Owner disposed these shares by way of transaction on Aug. 15, 2017. The company’s shares were given away at $21.16 per share worth to an income of some $3,779,176 on account of Novo Holdings A/S.
10% Owner, Novo Holdings A/S, sold 491,294 common shares of AnaptysBio, Inc. (ANAB) in the open market. In a transaction dated Aug. 07, 2017, the shares were put up for sale at an average price of $21.12, raking in a sum of $10,376,129. After this sale, 2,471,504 common shares of ANAB are directly owned by the insider, with total stake valued at $201,328,716.
In the transaction dated Aug. 03, 2017, the great number of shares disposed came courtesy the 10% Owner; Novo Holdings A/S disposed a total of 70,706 shares at an average price of $23.31, amounting to approximately $1,648,157. The insider now directly owns 2,962,798 shares worth $241,349,525.AnaptysBio, Inc. (ANAB) Analyst Guide
Several analysts have released their opinion on AnaptysBio, Inc. (NASDAQ:ANAB), with 6 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.14 average brokerage recommendation.